SUMMARY
INTRODUCTION
Fibroblast growth factors (FGFs) constitute a family of heparin-binding polypeptides involved in the regulation of biological responses such as growth, differentiation and angiogenesis. The FGF family currently consists of 23 members, with FGF-1 (acidic FGF) and FGF-2 (basic FGF) the most extensively studied. The biological effects of FGFs are mediated by four structurally related receptor tyrosine kinases, denoted FGFR-1, FGFR-2, FGFR-3 and FGFR-4. The binding of FGF to its receptor, results in receptor dimerization and subsequent autophosphorylation on specific tyrosine residues, within the intracellular domain (Ullrich and Schlessinger, 1990) . A number of autophosphorylation sites in the FGFR-1 have been identified (for a review, see Cross and Claesson-Welsh, 2001 ): Y463 in the juxtamembrane which is responsible for binding Crk (Larsson et al., 1999) , Y583/585 in the kinase insert, Y653/654 in the kinase domain which are critical for kinase activity, Y730, and the C-terminal Y766 which is the binding site for PLC-γ (Mohammadi et al., 1991) .
Unlike other receptor tyrosine kinases, the FGF receptors do not directly bind Grb2.
Instead, activation of the Ras/MEK/MAPK pathway is achieved via the phosphorylation of a 90 kDa protein denoted FRS2 (Klint et al., 1995; Kouhara et al., 1997) ). FRS2 lacks an SH2 domain, but contains a phosphotyrosine binding (PTB) domain which mediates phosphotyrosineindependent binding to the juxtamembrane region of the FGFR-1 (Xu et al., 1998) . Activation of FGFR-1 leads to the tyrosine phosphorylation of FRS2 on several sites, allowing the binding of Grb2 and the phosphotyrosine phosphatase Shp-2. Binding of both these molecules is required for maximal activation of MAPK (Hadari et al., 1998) .
The binding of PLC-γ to tyrosine 766 in the FGFR-1 results in the phosphorylation and activation of this molecule. Active PLC-γ hydrolyzes the membrane phospholipid phosphatidylinositol 4,5-bisphosphate (PIP 2 ), generating inositol 1,4,5-trisphosphate (IP 3 ) and diacylglycerol (DAG). IP 3 is responsible for releasing calcium from internal stores whilst DAG 4 activates certain PKC isoforms (Divecha and Irvine, 1995) . The physiological role of PLC-γ in FGFR-1 signaling has been determined by mutation of tyrosine 766 to phenylalanine (Y766F), which prevents the binding and subsequent activation of PLC-γ. A number of studies have reported that FGFR-1-mediated PLC-γ activation is not required for FGFR-1 mediated mitogenesis (Mohammadi et al., 1992; Peters et al., 1992) chemotaxis (Clyman et al., 1994; Landgren et al., 1998) and neurite outgrowth (Spivak-Kroizman et al., 1994) . However, recent data has shown that mutation of tyrosine 766 has a profound effect on FGFR-1-mediated cytoskeletal reorganization in endothelial cells (Cross et al., 2000) . Biochemical analysis has demonstrated that mutation of tyrosine 766 results in a reduced activation of MAPK, which occurs at the level of Raf (Huang et al., 1995) . However, the conclusions drawn from all these studies assume that PLC-γ is the sole protein binding to tyrosine 766 in the FGFR-1.
Shb is a ubiquitously expressed adaptor protein which was first identified as a seruminducible gene in insulin-producing βTC-1 cells (Welsh et al., 1994) . Shb contains a carboxy terminal SH2 domain, which interacts with the PDGF β-receptor (Welsh et al., 1994) , the FGFR-1 and the T-cell receptor-associated ζ-chain (Karlsson et al., 1995; Welsh et al., 1998) , a central PTB domain which interacts with phosphorylated p36/38 (LAT; Lindholm et al., 1999 ) and a number of N-terminal proline-rich motifs which mediate its interaction with the SH3 domains of Eps 8, p85α subunit of PI3-kinase, Grb2 and Src (Karlsson et al., 1995) . Overexpression of Shb in PC12 cells has been shown to enhance NGF-and FGF-stimulated neurite outgrowth , suggesting that Shb may play a role in FGF signaling.
We have used the immortalized brain endothelial cell line (IBE; (Kanda et al., 1996) ) and retroviral mediated gene transfer to generate a number of clones expressing chimeric receptors, composed of the extracellular domain of the PDGFR-α and the intracellular domain of the FGFR-1. We sought to define the molecular mechanism by which tyrosine 766, in the FGFR-1, regulates the MAPK pathway and mitogenicity, in endothelial cells.
MATERIALS AND METHODS

Antibodies and reagents.
The goat polyclonal anti-PDGFR-α (extracellular domain) antibody was purchased from R&D.
The rabbit polyclonal anti-FGFR-1 (intracellular domain) antibody was generated against a synthetic peptide encompassing the final 16 C-terminal amino acid residues in the FGFR-1. The rabbit polyclonal anti-Shb antibody was generated as previously described (Karlsson and Welsh, 1996) . The anti-FGFR monoclonal antibody (McAb6) was a kind gift from Dr. P. Maher (The Scripps Institute, La Jolla). The anti-FRS2 polyclonal antibody was a kind gift from Dr. I. Lax (New York University). The anti-Shp-2 antibody was purchased from Santa Cruz. Phorbol 12-myristate 13-acetate (PMA), leupeptin, chloroquine, polybrene, puromycin, fibronectin (Human), fatty-acid free bovine serum albumin (BSA) and gelatin (porcine) were purchased from Sigma. FGF-2 and isopropyl-1-thio-β-D-galactopyranoside (IPTG) were purchased from Boehringer Mannheim. The BCA protein assay kit was purchased from Pierce.
PDGF-AA and murine interferon-γ (IFN-γ) were purchased from Peprotech. AG-X8 anion exchange resin was from BioRad. All cell culture media was purchased from Life Technologies. IBE cells were routinely cultured on 1% gelatin-coated dishes in Ham's F-12 medium containing 15% fetal calf serum (FCS) and 20 U/ml IFN-γ at 33°C (Kanda et al., 1996) . For experimental purposes, cells were trypsinized and plated at the required density on plastic dishes coated with fibronectin (20 µg/ml) and 0.1% gelatin in Ham's F-12 medium containing 15% FCS in the absence of IFN-γ and cultured at 33 o C. The chimeric PDGFR-α/FGFR-1 (denoted α/wt) cDNA and PDGFR-α/FGFR-1:Y766F mutant denoted (α/Y766F) cDNA were constructed as previously described (Landgren et al., 1998) . The chimeric receptor cDNAs were inserted into the retroviral vector pBABE Puro and all constructs verified by sequencing. The wild-type Shb cDNA and R522K Shb mutant cDNA (point mutation resulting in the inactivation of SH2 domain binding; ) were inserted into the retroviral vector pBABE Puro. The packaging cell line Bosc-23 (Pear et al., 1993) (Plevin et al., 1990) .
Expression and purification of GST-fusion proteins.
The bacteria Escherichia coli (BL-21) harboring the plasmid pGEX-KG containing the Raf1-Ras binding domain (Raf1-RBD; amino acids 1 to 149) fused to glutathione S-transferase (GST) was kindly provided by Dr. Bengt Hallberg (University of Umeå, Sweden). The culture was grown overnight at 37 o C with agitation. The next day the bacterial culture was split 1:10 and grown for 1 h at 37 o C with shaking. Expression was induced by the addition of 1 mM IPTG for 3 h at 37 o C with shaking. The bacteria were lysed by sonication in 20 mM Tris pH 7.5 containing 1% Triton 8 X-100, 1 mM EDTA, 1 mM EGTA, 10 µg/ml aprotinin, 10 µg/ml leupeptin, 1 mM PMSF and 1 mM DTT. The lysate was clarified by centrifugation and incubated with glutathione sepharose for 1 h at 4 o C with end-over-end mixing. The sepharose beads were washed four times in lysis buffer and finally resuspended as a 1:1 slurry in lysis buffer containing 50% glycerol and stored at -20 o C. The Shb-SH2-GST fusion protein was prepared as previously described (Welsh et al., 1994) .
Active Ras pulldown assay.
The activation status of Ras was determined by using a GST-fusion protein of the Ras-binding domain (RBD) of Raf-1 (1-149), which has been shown to have a high affinity for active GTPRas (Taylor and Shalloway, 1996) . Cells were plated at 6 x 10 5 cells per 10 cm dish in Ham's F-12 containing 15% FCS and cultured for 48 h at 33 o C. The medium was changed to Ham's F-12 containing 0.2% BSA and the cells grown for a further 24 h. Cells were stimulated for various periods with either 30 ng/ml PDGF-AA, 10 ng/ml FGF-2 or buffer. Cells were washed in icecold PBS and lysed in lysis buffer containing 20 mM Tris pH 7.5 containing 1% Triton X-100, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 10 mM MgCl 2 , 10 µg/ml aprotinin, 10 µg/ml leupeptin, 1 mM PMSF and 1 mM DTT. Lysates were clarified by centrifugation and 500 µg of total cellular protein incubated with approximately 50 µg of GST-Raf1-(RBD) fusion protein for 1h at 4 o C with end-over-end mixing. The beads were collected by centrifugation and washed four times in lysis buffer. The beads were then resuspended in SDS-sample buffer and samples boiled for 5 min. Proteins were resolved by SDS-PAGE using a 15% gel, transferred electrophoretically and visualized using enhanced chemiluminescence (ECL).
Precipitation and Immunoblotting.
Cells were seeded at 2 x 10 5 per well of 6-well plates in Hams F-12 containing 15% FCS and grown at 33 o C for 48 h. The medium was changed to Ham's F-12 containing 0.2% BSA and cells incubated at 33 o C for 24 h. Cells were then stimulated with either medium, FGF-2 (10 ng/ml) or PDGF-AA (30 ng/ml) for various times at 37 o C. Following stimulation, cells were rinsed in icecold PBS and lysed in 20 mM Tris/HCl pH 7.5, 150 mM NaCl, 1% Triton X-100, 10% glycerol, 500 µM Na 3 VO 4 , 10 µg/ml aprotinin, 10 µg/ml leupeptin and 1 mM PMSF. Lysates were transferred to Eppendorf tubes and centrifuged at 14,000 x g for 20 min at 4 o C. The supernatants were transferred to fresh Eppendorf tubes and protein determined by BCA protein assay. 
RESULTS
Characterization of transfected cells.
The immortomouse brain endothelial (IBE) cells display a number of markers characteristic of primary endothelial cells (Kanda et al., 1996) and represent a useful in vitro cell model to study FGF-mediated signal transduction in endothelial cell proliferation. We decided to study the role of tyrosine 766, the PLC-γ binding site, in FGFR-1 mediated signal transduction. The IBE cells express an endogenous FGFR-1 but show no expression of PDGFR-α (Kanda et al., 1996) , therefore we chose to transfect them with a chimeric receptor cDNA composed of the extracellular part of the PDGFR-α fused to the intracellular part of the FGFR-1 ( Figure 1A ).
Such a receptor can be specifically stimulated with the ligand PDGF-AA and transduce FGFR-1-specific effects (Landgren et al., 1998) . Stable IBE cell clones expressing the chimeric receptors were generated by use of retroviral-mediated gene delivery. Clones expressing similar levels of the chimeric receptor were identified by Western blotting ( Figure 1B ). The α/wt and α/Y766F
receptors showed similar levels of ligand-inducible kinase activity, indicating that the Y766F mutation did not affect receptor kinase activity ( Figure 1C ). At least two separate wild-type and Y766F receptor-expressing clones were used for all subsequent experiments with identical results obtained to those presented.
Analysis of PLC activity, showed that whilst all cell types responded to FGF-2-stimulation, cells expressing the α/Y766F receptor failed to stimulate PLC activity in response to PDGF-AA ( Figure 2A ). This is consistent with tyrosine 766 being the binding site for PLC-γ and required for activation of this enzyme. Previous reports have shown that tyrosine 766 is not required for a mitogenic response to FGF. However, in the chimeric receptor expressing IBE cells, loss of tyrosine 766 resulted in a 50% decrease in thymidine incorporation in response to PDGF-AA treatment, compared to the wild-type chimeric receptor, indicating that tyrosine 766
was required for a full mitogenic response ( Figure 2B ). Analysis of mitogenicity in the Vec, α/wt and α/Y766F cells revealed that FGF-2 showed a similar response to FCS, indicating that FGF-2 could evoke a full mitogenic response in all cells ( Figure 2C ). However, we noticed that in the α/wt and α/Y766F cells, both FGF and FCS could not stimulate a mitogenic responses to the same degree as in the Vec cells. We believe that this was due to the elevated basal mitogenic activity, which seemed to be a feature of the chimeric receptor expressing cells.
Tyrosine 766 is required for sustained activation of FRS2 and the Ras/MEK/MAPK pathway
Tyrosine 766 has been previously shown to be required for maximal activation of p42/44
MAPK (Huang et al., 1995) . Tyrosine 766 has been shown to bind PLC-γ which results in the generation of DAG and IP 3 . The resulting rise in intracellular calcium and generation of DAG leads to the activation of a number of PKC isoforms. Since PKC has been shown to activate MAPK in a variety of cells (Chao et al., 1992; Schonwasser et al., 1998) , we were interested in the potential regulation of FGFR-1-mediated MAPK activation by PKC; such a mechanism may explain the reduced MAPK activation in cells expressing the α/Y766F mutant receptor. Pretreatment of IBE cells with the PKC inhibitor GF109203X (GFX), which inhibits the classical and atypical PKC isoforms (Toullec et al., 1991) , failed to inhibit FGF-2 stimulated MAPK activity ( Figure 5A ).
The phorbol ester, PMA, also stimulated MAPK activity, which was inhibited by GFX, indicating that the drug was able to block PKC activation in these cells. Pretreatment with the calcium chelator BAPTA-AM, either alone or in conjunction with GFX, also failed to inhibit FGF-2 mediated MAPK activation ( Figure 5A ). Pretreatment with another bisindolymaleimide PKC inhibitor, Gö 6983, also failed to inhibit FGF-2 stimulated PKC activity in the IBE cells (data not shown). Recently it has been shown that certain PKC isoforms can also be activated via PI3-kinase mediated activation of PDK1 (Le Good et al., 1998) . Pretreatment with the PI3-kinase inhibitors wortmannin and LY294002, had no effect on FGF-2 stimulated MAPK activation in the IBE cells ( Figure 5B ), suggesting that PI3-kinase activity was not required for FGFR-1 mediated MAPK activation. Identical results using PKC inhibitors and PI3-kinase inhibitors were obtained using cells expressing the α/wt chimeric receptor stimulated with PDGF-AA (data not shown). Taken together, this suggests that FGFR-1 mediated MAPK activation is not dependent on DAG and Ca 2+ mediated activation of the classical PKC isoforms or DAG-mediated activation of the novel PKC isoforms. Therefore, the reduction in MAPK activity, seen in cells expressing the α/Y766F chimeric receptor, cannot be explained by a loss of PLC-γ mediated PKC activity.
Another pathway which has been implicated in FGF-2-stimulated MAPK activation is protein kinase A (PKA; (D'Angelo et al., 1997)), which is known to inhibit MAPK activation via phosphorylation of Raf (Cook and McCormick, 1993) . Preincubation of IBE cells with the cell permeable cAMP analogue, 8-bromo-cAMP and the PKA activator forskolin had no effect on FGF-2-stimulated MAPK activity ( Figure 5C ). The Src-family inhibitor PP2 also showed no effect on FGF-2 stimulated MAPK activity ( Figure 5D ). Taken together, this suggests that PKA and Src activity are not critical for FGFR-1 mediated MAPK activity.
To confirm that FGFR-1-mediated activation of MAPK was downstream of the Ras/Raf/MEK cascade, we utilised the well characterized MEK inhibitor PD98059 (Alessi et al., 1995) and a recent, more potent MEK inhibitor, U0126 (Favata et al., 1998) . Preincubation with PD98059 showed only a partial inhibition of FGF-2-stimulated MAPK activation ( Figure 5D ).
In contrast, U0126 was able to inhibit FGF-2-stimulated MAPK activation ( Figure 5D ).
Interestingly, a similar inhibition profile of FGF-2-stimulated MAPK phosphorylation with PD98059 and U0126 has also been observed in Swiss 3T3 cells (Maher, 1999) .
The Shb adaptor protein binds to tyrosine 766 and regulates the Ras/MEK/MAPK pathway.
To explain the loss of regulation of FRS2 and the Ras/MEK/MAPK pathway in the Y766F cells we were interested in other candidate proteins that may bind to Y766, in addition to PLC-γ. The Shb adaptor protein has been previously shown to bind to the consensus motif pY-T/V/I-X-L (Karlsson et al., 1995) . The closest match to this site in the FGFR-1 is tyrosine 766.
To investigate if Shb could bind directly to the FGF receptor, untransfected IBE cells were stimulated with FGF-2. Shb was immunoprecipitated and analyzed for co-immunoprecipitation of the FGF receptor. As shown in Figure 6A , Shb was found to complex with the FGF receptor upon agonist stimulation. To determine if Shb bound to tyrosine 766 in the FGFR-1, we immunoprecipitated Shb from cells expressing the chimeric receptors, following stimulation with the ligand PDGF-AA. We then Western blotted with an antibody that specifically detected the extracellular domain of the PDGFR-α. Figure 6B shows that we detected an association between the chimeric receptor and Shb only in the stimulated α/wt cells and not in the α/Y766F cells. To certify further the interaction between Shb and the chimeric receptor, we also performed a kinase assay on Shb immunoprecipitates. Figure 6C shows that we detected a phosphorylated band of To investigate the molecular mechanism by which Shb may regulate both FRS2
and Shp-2 phosphorylation we analyzed the potential interaction of Shb and Shp-2. 
Immunoprecipitation of Shb revealed that
DISCUSSION
PLC-γ was the first protein identified to bind directly to the FGFR-1, and subsequently, its role in FGF-mediated biological responses has been extensively investigated. Mutation of tyrosine 766, the PLC-γ binding site, has revealed that PLC-γ activity is not required for FGFR-1-mediated mitogenicity (Mohammadi et al., 1992; Peters et al., 1992) . In contrast, other studies have shown that mutation of tyrosine 766 can affect FGFR-1 mediated proliferation of L6 myoblasts (Klint et al., 1995) and to a lesser degree of Ba/F3 cells (Huang et al., 1995) . Previous work on signaling cascades downstream of tyrosine 766, the PLC-γ binding site in the FGFR-1, has shown that mutation of tyrosine 766 leads to a reduction in FGFR-1-mediated MAPK activity, an effect attributed to loss of PKC mediated Raf phosphorylation (Huang et al., 1995) . A number of PKC isoforms have been shown to directly phosphorylate Raf-1 (Cai et al., 1997; Schonwasser et al., 1998) and regulate MEK and MAPK phosphorylation in vivo. In the IBE cells, the broad-spectrum PKC inhibitors GF109203X and Gö 6983 had no effect on FGF-mediated MAPK activation ( Figure 5 ). Therefore, whilst we indeed noticed a reduction in MAPK activity with the α/Y766F mutation (Figure 3 ), FGFR-1-mediated MAPK activation was not dependent on PKC activation. The ability of FGF to stimulate MAPK, independent of PKC, has also been observed in L6 myoblasts (van Dijk and van Blitterswijk, 1998) , suggesting that it is not confined to IBE cells.
The ability of tyrosine 766 to regulate MAPK activity was dependent upon FRS2 phosphorylation. Phosphorylation of FRS2 is known to be critical for FGF-stimulated MAPK activation (Kouhara et al., 1997) A search for other proteins that may bind to tyrosine 766 in the FGFR-1 led us to examine Shb, an adaptor protein which has been previously reported to affect FGF-stimulated MAPK activation in PC12 cells . The preferred binding sequence for the Shb SH2 domain is pY-T/V/I-X-L with Leu in position +3 as the main determinant (Karlsson et al., 1995) . In the FGFR-1, the closest match is Y766, which has the sequence pY-L/A/L. Shb bound to the endogenous FGF receptors on IBE cells, which was mediated through tyrosine 766 in the FGFR-1 (Figure 6B and C). Use of a GST-Shb-SH2 domain fusion protein indicated that the SH2 domain of Shb interacts directly with phosphorylated tyrosine 766 in the FGFR-1.
Phosphorylation of Shb was inhibited in cells expressing the Y766F chimeric receptor suggesting that receptor association is required for phosphorylation. FGF-2-stimulation of IBE cells overexpressing a Shb SH2 domain mutant (R522K) revealed a perturbment in the Ras/MEK/MAPK pathway ( Figure 9A ), similar to that seen in cells expressing the α/Y766F chimeric receptor mutant (Figure 3) . In both instances, there was a severe reduction of FRS2 phosphorylation in response to FGFR-1 activation.
In exploring the molecular mechanism whereby Shb modulates FRS2 phosphorylation, we discovered that both the Y766F mutation ( Figure 4A and B) and expression of a Shb mutant 20 ( Figure 9B and C), perturbed the phosphorylation of the tyrosine phosphatase Shp-2 and its association with FRS-2. Previous work has shown that association of FRS-2 and Shp-2 is required for efficient FGFR-1 mediated FRS2 phosphorylation and activation of the MAPK cascade (Hadari et al., 1998) . Overexpression of Shb potentiated the FGF-mediated phosphorylation of Shp-2 and its association with FRS-2, further suggesting that Shb could directly regulate Shp-2 phosphorylation and its association with FRS-2. However, we observed no concomitant increase in the phosphorylation of FRS2 upon overexpression of wild-type Shb, suggesting that in the IBE cells, the endogenous association of Shp-2 and FRS2 was sufficient to cause maximal phosphorylation of FRS2. The mechanism whereby Shp-2 regulates FRS2 phosphorylation and MAPK activation remains obscure, although it has been demonstrated that the catalytic activity of Shp-2 is required for sustained MAPK activation in response to FGF (Hadari et al., 1998 ).
We could not detect any direct association between Shb and FRS2 (data not shown),
suggesting that Shb affects FRS2 phosphorylation indirectly. However, we did find that Shb was constitutively associated with Shp-2 (Figure 10 ), providing a molecular link between Shb and FRS2. This interaction was surprising, since the Shb amino-acid sequence (Welsh et al., 1994) , does not contain the consensus pY-I/V-X-V/I/L/P binding region for the SH2 domains of Shp-2 (Songyang et al., 1993) . It is possible that Shp-2 associates with Shb via another binding mechanism. Indeed, examination of the crystal structure of Shp-2, has revealed that the Nterminal SH2 domain of Shp-2 can bind intramolecularly to the phosphatase domain, in a phosphotyrosine independent manner (Hof et al., 1998) . However, it is also conceivable that Shp-2 interacts indirectly with Shb, possibly via Grb2, which is known to associate with the Nterminal proline rich domain in Shb, via its SH3 domain (Karlsson et al., 1995) , and with phosphorylated tyrosine residues in Shp-2, via its SH2 domain (Vogel and Ullrich, 1996) .
Therefore, it is possible that Shp-2 acts as a bridge to link Shb and FGFR-1 activation to FRS2
phosphorylation and the subsequent activation of MAPK.
Previous reports have shown that FRS2 interacts constitutively with the juxtamembrane region of the FGFR, via its PTB domain, in a phosphorylation independent manner (Xu et al., 1998; Ong et al., 2000) . Therefore, the data presented here suggests that both Shb and PLC-γ bind to tyrosine 766 in the FGFR-1. A recent report has shown that in addition to tyrosine 766, tyrosines 677 and 701
are also required for FGFR-1-mediated PLC-γ activation (Foehr et al., 2001) , suggesting that a number of additional residues also regulate PLC-γ binding; although tyrosine 766 appears to be the main binding site. The PLC-γ pathway is known to couple to PKC/Ca
2+
. The novel Shb pathway is able to regulate Shp-2 and FRS2 phosphorylation and subsequently the Ras/MEK/MAPK cascade leading to a mitogenic response (Figure 12 ). However, since both mutation of tyrosine 766 ( Figure 3B ) and expression of a Shb SH2 domain mutant ( Figure 8B) did not completely inhibit all Ras/MEK/MAPK activity in the IBE cells, it is likely that the 22 FGFR-1 activates the Ras/MEK/MAPK pathway by more than one mechanism. Indeed, we have previously reported that Y463, in the juxtamembrane domain of the FGFR-1, can also affect FRS2 phosphorylation and MAPK activity in endothelial cells (Larsson et al., 1999) . The physiological importance of the MAPK cascade is highlighted by the fact that in the chicken chorioallantoic membrane (CAM) assay, addition of the MEK inhibitor PD 98059, prevents FGF-mediated angiogenesis (Eliceiri et al., 1998) . The proliferation of endothelial cells is an important step in angiogenesis as the endothelial cells must migrate, proliferate and eventually differentiate to form a new, lumen containing vessel (Cross and Claesson-Welsh, 2001 ). By regulating the mitogenic response, our data suggests that Shb may play an important role in regulating FGF-mediated angiogenesis. Proteins were transferred electrophoretically and blotted for active MEK using a phosphospecific MEK antibody or for active MAPK using a phospho-specific (p42/44) MAPK antibody.
Blots were stripped and reprobed with either an anti-MEK antibody or an anti-(p42/44) MAPK antibody. 
